Aptorum Group
APM
Market cap $3.73M

0.6820 USD

-0.4180

38.00%

At close Nov 15, 4:00 PM EST

After hours

0.7299

+0.0479

7.02%

1 day

-38.00%

5 days

-43.17%

1 month

-61.25%

3 months

-78.42%

6 months

-85.49%

Year to date

-68.86%

1 year

-55.71%

5 years

-99.57%

10 years

-99.52%

About: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Employees: 3

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.08% less ownership

Funds ownership: 2.97% [Q2] → 1.89% (-1.08%) [Q3]

50% less funds holding

Funds holding: 4 [Q2] → 2 (-2) [Q3]

74% less capital invested

Capital invested by funds: $384K [Q2] → $99.7K (-$284K) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for APM.

See Analyst Rankings

Financial journalist opinion

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, “Throughout 2023, we have maintained a.

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

5 Investors Betting Big on Aptorum (APM) Group

Clinical-stage biopharmaceutical firm Aptorum (NASDAQ: APM ) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what's helping APM stock rocket higher.

5 Investors Betting Big on Aptorum (APM) Group

Why Is Aptorum (APM) Stock Up 346% Today?

Aptorum (NASDAQ: APM ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group. This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete.

Why Is Aptorum (APM) Stock Up 346% Today?

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Ap.

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. “During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our A.

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office.

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on Decemb.

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

See News Rankings

Charts implemented using Lightweight Charts™